drugset
drugset / Trial / NCT04591626

A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes

NCT04591626 ↗

Phase 3 Completed 291 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.

Timeline

Start
2020-12-07
Primary completion
2022-04-28
Completion
2022-04-28

Outcome

Met primary endpoint

registry analysis (superiority test); 1.5 mg Dulaglutide vs Placebo; p <0.001; LS Mean Difference -0.95 (95% CI -1.14 to -0.77); Mixed Models Analysis NCT04591626 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Dulaglutide Peptide 1.5 mg Subcutaneous
Background insulin glargine Protein / enzyme biologic — Subcutaneous

Indications

type 2 diabetes mellitus